share_log

Earnings Call Summary | Avid Bioservices(CDMO.US) Q3 2024 Earnings Conference

Earnings Call Summary | Avid Bioservices(CDMO.US) Q3 2024 Earnings Conference

業績電話會議摘要 | Avid 生物服務 (CDMO.US) 2024 年第三季度業績會議
富途資訊 ·  04/30 09:52  · 電話會議

The following is a summary of the Avid Bioservices, Inc. (CDMO) Q3 2024 Earnings Call Transcript:

以下是 Avid 生物服務公司 (CDMO) 2024 年第三季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Avid Bioservices saw a significant increase in revenues by over 30% in Q3 2024 compared to Q2 2024, culminating in earnings of $33.8 million.

  • Gross margin for Q3 was relatively low at 7% compared to 26% in Q3 2023.

  • The net loss for Q3 2024 was $6 million, considerably higher than the $0.2 million of the same period the previous year.

  • The company maintained cash and cash equivalents of $30.7 million as of January 31, 2024.

  • 與2024年第二季度相比,Avid Bioservices在2024年第三季度的收入大幅增長了30%以上,最終收益爲3,380萬美元。

  • 第三季度的毛利率相對較低,爲7%,而2023年第三季度爲26%。

  • 2024年第三季度的淨虧損爲600萬美元,大大高於去年同期的20萬美元。

  • 截至2024年1月31日,該公司維持了3,070萬美元的現金及現金等價物。

Business Progress:

業務進展:

  • Business growth was supported by new project agreements, resulting in a backlog of over $200 million.

  • The Q3 2024 saw the successful opening of their cell and gene therapy facility and completion of the three-year expansion program.

  • The company refinance of convertible notes extended the debt maturity to 2029, improving its financial flexibility.

  • With the operational CGT facility, Avid is now able to engage customers with a complete product offering, expected to improve cash flow and margins.

  • An increase in early-stage project bookings indicates an improving financing environment for biotechs.

  • Future capital expenditure is planned for maintenance and software, following the completion of the current expansion.

  • The company looks forward to closing the fiscal year with a CapEx of around $32 million.

  • 業務增長得到了新項目協議的支持,導致積壓的項目超過2億美元。

  • 2024年第三季度,他們的細胞和基因治療設施成功開放,爲期三年的擴張計劃完成。

  • 該公司的可轉換票據再融資將債務到期日延長至2029年,提高了其財務靈活性。

  • 藉助 CGT 設施的運營,Avid 現在能夠爲客戶提供完整的產品,有望改善現金流和利潤。

  • 早期項目預訂量的增加表明生物技術公司的融資環境有所改善。

  • 在當前的擴張完成後,未來的資本支出計劃用於維護和軟件。

  • 該公司期待以約3200萬美元的資本支出結束本財年。

More details: Avid Bioservices IR

更多詳情: Avid 生物服務 IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論